Iovance Biotherapeutics to Present at Upcoming Conference

Company Overview - Iovance Biotherapeutics, Inc. is focused on innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for cancer patients [2] - The company aims to be a global leader in TIL therapies, utilizing the human immune system to target diverse cancer cells [2] - Iovance's Amtagvi is the first FDA-approved T cell therapy for a solid tumor indication, showcasing the company's commitment to continuous innovation in cell therapy [2] Upcoming Events - Senior leadership of Iovance Biotherapeutics will present at the Goldman Sachs Global Healthcare Conference on June 11, 2025, at 1:20 p.m. ET [1] - The presentation will be available via live and archived webcasts on the company's investor relations website [1] Product Development - The Iovance TIL platform has shown promising clinical data across multiple solid tumors, indicating potential for future growth and development [2] - The company is also exploring gene-edited cell therapy as part of its innovation strategy [2]